Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,502 Infectious Disease
clinical trials

Clostridium Difficile Infection Clinical Trial
Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 5/26/2016
University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 5/26/2016
Remington Davis Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 5/26/2016
University of Texas School of Public Health
mi
from
Houston, TX
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 5/26/2016
Drexel University/Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clostridium Difficile Infection Clinical Trial
Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
Status: Enrolling, Phase II
Updated: 5/26/2016
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Reproductive Clinical Trial
Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Gillings School of Public Health
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ichthyosis Clinical Trial
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
Status: Enrolling
Updated: 1/5/2018
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
HIV Clinical Trial
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
Status: Enrolling, Phase IV
Updated: 3/6/2018
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Third Party Anti-Viral Cytotoxic T-Cells
Status: Enrolling, Phase II
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bacterial Infections Clinical Trial
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Status: Enrolling, Phase I
Updated: 12/31/1969
Duke Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Bacterial Infections Clinical Trial
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Status: Enrolling, Phase I
Updated: 12/31/1969
Children's Mercy Kansas City
mi
from
Kansas City, KS
Click here to add this to my saved trials
Bacterial Infections Clinical Trial
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Bacterial Infections Clinical Trial
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Status: Enrolling, Phase I
Updated: 12/31/1969
LSU Health Sciences Center - Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Latent Tuberculosis Clinical Trial
Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging
Status: Enrolling
Updated: 10/25/2017
Pima County Health Department
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Status: Enrolling, Phase
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases, Other Clinical Trial
Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)
Status: Enrolling, Phase
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Tuberculosis Clinical Trial
Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection
Status: Enrolling
Updated: 4/3/2017
VA Palo Alto Health Care System (VAPAHCS)
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Acute Otitis Media Clinical Trial
Shared Decision Making in Parents of Children With Acute Otitis Media
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Montefiore Medical Center-Einstein Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Fasciitis, Plantar Clinical Trial
ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis
Status: Enrolling
Updated: 12/31/1969
Geisinger
mi
from
Danville, PA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: Enrolling, Phase I
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Systemic Lupus Erythematosus Clinical Trial
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Status: Enrolling, Phase II
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Systemic Lupus Erythematosus Clinical Trial
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Status: Enrolling, Phase II
Updated: 12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
HSV Infection Clinical Trial
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Enrolling, Phase II
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
HSV Infection Clinical Trial
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Enrolling, Phase II
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
HSV Infection Clinical Trial
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Enrolling, Phase II
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
HSV Infection Clinical Trial
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Enrolling, Phase II
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
HSV Infection Clinical Trial
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Enrolling, Phase II
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT
Status: Enrolling
Updated: 4/18/2017
Central Texas Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Urinary Tract Infections Clinical Trial
Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Status: Enrolling, Phase IV
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lower Respiratory Tract Infections Clinical Trial
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection
Status: Enrolling, Phase
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
HIV-1 Infection Clinical Trial
Early ART to Limit Infection and Establishment of Reservoir
Status: Enrolling, Phase II
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
HIV-1 Infection Clinical Trial
Early ART to Limit Infection and Establishment of Reservoir
Status: Enrolling, Phase II
Updated: 12/31/1969
31443 Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases Clinical Trial
Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection
Status: Enrolling
Updated: 3/27/2017
Children's Hospital of Richmond at VCU
mi
from
Richmond, VA
Click here to add this to my saved trials
Endocrinology, Immunology / Infectious Diseases, Rheumatology Clinical Trial
Aerobic Exercise in Women With Systemic Lupus Erythematosus
Status: Enrolling, Phase I
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Blank Children's Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
The Children's Hospital at TriStar Centennial
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington DC,
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Eastern Maine Medical Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Randall Children's Hospital at Legacy Emanuel
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital and Medical Center of Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
1 … 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 … 65